Cargando…

Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy

SIMPLE SUMMARY: Immunotherapy, most notably immune checkpoint inhibitors (ICIs), has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Although some patients respond well to ICIs, many patients do not benefit from ICIs, leading to disease progression and/or immune-related...

Descripción completa

Detalles Bibliográficos
Autores principales: Honrubia-Peris, Beatriz, Garde-Noguera, Javier, García-Sánchez, Jose, Piera-Molons, Nuria, Llombart-Cussac, Antonio, Fernández-Murga, María Leonor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428366/
https://www.ncbi.nlm.nih.gov/pubmed/34503087
http://dx.doi.org/10.3390/cancers13174280
_version_ 1783750365865312256
author Honrubia-Peris, Beatriz
Garde-Noguera, Javier
García-Sánchez, Jose
Piera-Molons, Nuria
Llombart-Cussac, Antonio
Fernández-Murga, María Leonor
author_facet Honrubia-Peris, Beatriz
Garde-Noguera, Javier
García-Sánchez, Jose
Piera-Molons, Nuria
Llombart-Cussac, Antonio
Fernández-Murga, María Leonor
author_sort Honrubia-Peris, Beatriz
collection PubMed
description SIMPLE SUMMARY: Immunotherapy, most notably immune checkpoint inhibitors (ICIs), has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Although some patients respond well to ICIs, many patients do not benefit from ICIs, leading to disease progression and/or immune-related adverse events. Biological markers can help to improve patient selection. However, currently available markers such as PD-1 and its ligand (PD-L1) have important limitations. For this reason, new biomarkers obtained by non-invasive methods are urgently needed. In the present review, we describe recent advances in the development of novel soluble biological markers (e.g., circulating immune cells, TMB, circulating tumor cells, circulating tumor DNA, soluble factor PD-L1, tumor necrosis factor, etc.) for patients with NSCLC treated with immunotherapy. ABSTRACT: Numerous targeted therapies have been evaluated for the treatment of non-small cell lung cancer (NSCLC). To date, however, only a few agents have shown promising results. Recent advances in cancer immunotherapy, most notably immune checkpoint inhibitors (ICI), have transformed the treatment scenario for these patients. Although some patients respond well to ICIs, many patients do not benefit from ICIs, leading to disease progression and/or immune-related adverse events. New biomarkers capable of reliably predicting response to ICIs are urgently needed to improve patient selection. Currently available biomarkers—including programmed death protein 1 (PD-1) and its ligand (PD-L1), and tumor mutational burden (TMB)—have major limitations. At present, no well-validated, reliable biomarkers are available. Ideally, these biomarkers would be obtained through less invasive methods such as plasma determination or liquid biopsy. In the present review, we describe recent advances in the development of novel soluble biomarkers (e.g., circulating immune cells, TMB, circulating tumor cells, circulating tumor DNA, soluble factor PD-L1, tumor necrosis factor, etc.) for patients with NSCLC treated with ICIs. We also describe the potential use of these biomarkers as prognostic indicators of treatment response and toxicity.
format Online
Article
Text
id pubmed-8428366
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84283662021-09-10 Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy Honrubia-Peris, Beatriz Garde-Noguera, Javier García-Sánchez, Jose Piera-Molons, Nuria Llombart-Cussac, Antonio Fernández-Murga, María Leonor Cancers (Basel) Review SIMPLE SUMMARY: Immunotherapy, most notably immune checkpoint inhibitors (ICIs), has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Although some patients respond well to ICIs, many patients do not benefit from ICIs, leading to disease progression and/or immune-related adverse events. Biological markers can help to improve patient selection. However, currently available markers such as PD-1 and its ligand (PD-L1) have important limitations. For this reason, new biomarkers obtained by non-invasive methods are urgently needed. In the present review, we describe recent advances in the development of novel soluble biological markers (e.g., circulating immune cells, TMB, circulating tumor cells, circulating tumor DNA, soluble factor PD-L1, tumor necrosis factor, etc.) for patients with NSCLC treated with immunotherapy. ABSTRACT: Numerous targeted therapies have been evaluated for the treatment of non-small cell lung cancer (NSCLC). To date, however, only a few agents have shown promising results. Recent advances in cancer immunotherapy, most notably immune checkpoint inhibitors (ICI), have transformed the treatment scenario for these patients. Although some patients respond well to ICIs, many patients do not benefit from ICIs, leading to disease progression and/or immune-related adverse events. New biomarkers capable of reliably predicting response to ICIs are urgently needed to improve patient selection. Currently available biomarkers—including programmed death protein 1 (PD-1) and its ligand (PD-L1), and tumor mutational burden (TMB)—have major limitations. At present, no well-validated, reliable biomarkers are available. Ideally, these biomarkers would be obtained through less invasive methods such as plasma determination or liquid biopsy. In the present review, we describe recent advances in the development of novel soluble biomarkers (e.g., circulating immune cells, TMB, circulating tumor cells, circulating tumor DNA, soluble factor PD-L1, tumor necrosis factor, etc.) for patients with NSCLC treated with ICIs. We also describe the potential use of these biomarkers as prognostic indicators of treatment response and toxicity. MDPI 2021-08-25 /pmc/articles/PMC8428366/ /pubmed/34503087 http://dx.doi.org/10.3390/cancers13174280 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Honrubia-Peris, Beatriz
Garde-Noguera, Javier
García-Sánchez, Jose
Piera-Molons, Nuria
Llombart-Cussac, Antonio
Fernández-Murga, María Leonor
Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
title Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
title_full Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
title_fullStr Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
title_full_unstemmed Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
title_short Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
title_sort soluble biomarkers with prognostic and predictive value in advanced non-small cell lung cancer treated with immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428366/
https://www.ncbi.nlm.nih.gov/pubmed/34503087
http://dx.doi.org/10.3390/cancers13174280
work_keys_str_mv AT honrubiaperisbeatriz solublebiomarkerswithprognosticandpredictivevalueinadvancednonsmallcelllungcancertreatedwithimmunotherapy
AT gardenoguerajavier solublebiomarkerswithprognosticandpredictivevalueinadvancednonsmallcelllungcancertreatedwithimmunotherapy
AT garciasanchezjose solublebiomarkerswithprognosticandpredictivevalueinadvancednonsmallcelllungcancertreatedwithimmunotherapy
AT pieramolonsnuria solublebiomarkerswithprognosticandpredictivevalueinadvancednonsmallcelllungcancertreatedwithimmunotherapy
AT llombartcussacantonio solublebiomarkerswithprognosticandpredictivevalueinadvancednonsmallcelllungcancertreatedwithimmunotherapy
AT fernandezmurgamarialeonor solublebiomarkerswithprognosticandpredictivevalueinadvancednonsmallcelllungcancertreatedwithimmunotherapy